Dario Launches DarioIQ™ AI Integration in Dario Health App with Direct-to-Consumer First Version for Hypertension Members

Rhea-AI Summary

Dario Health (NASDAQ: DRIO) launched DarioIQ™, a new conversational AI layer in the Dario Health app, rolling out a direct-to-consumer first version on Dec 10, 2025 to an opt-in cohort of hypertension members.

DarioIQ™ integrates behavioral insights, real-time biometric interpretation, device connectivity and human coaching across three components — Advisor, Sentinel and Strategist — and builds on the company’s proprietary AI models and 13 billion real-world data points. The company plans staged expansion to employers and health plans and to other chronic pathways including diabetes and weight management, prioritizing safety and clinical validation.

Key Figures

Real-world data points 13 billion Dataset underpinning DarioIQ AI models

AI components 3 modules Advisor, Sentinel and Strategist within DarioIQ

Market Reality Check

$12.16 Last Close

Volume Volume 19,332 is at 0.65x the 20-day average of 29,738, suggesting limited pre-launch positioning. low

Technical Shares at $12.16 are trading below the 200-day MA of $12.87 and 60.77% under the 52-week high of $31.00.

Peers on Argus 1 Up 1 Down

Sector peers showed mixed moves: MGRX up 8.93%, BFRG up 1.79%, while HCTI was down 1.30% and VSEE down 2.64%. Momentum scanner flagged BEAT up 60.15% and HCTI down 4.85%, indicating stock-specific action rather than a broad sector trend.

Common Catalyst At least one peer, HCTI, also had AI-related news, but overall moves appear idiosyncratic rather than a unified AI or health-information trade.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 04	Clinical outcomes data	Positive	+1.3%	JMIR Cardio study showing sustained blood pressure improvements from Dario platform usage.
Dec 02	Commercial wins	Positive	+0.8%	Company far exceeded 2025 new client target with 79 accounts signed YTD.
Nov 24	Cost-savings study	Positive	-7.2%	JMIR study showing $5,077 annual medical cost savings and lower utilization for users.
Nov 13	Q3 2025 earnings	Negative	-15.6%	Q3 revenue decline with losses despite higher gross margins and ARR-focused strategy.
Nov 12	Health economics data	Positive	-3.3%	ISPOR Europe claims data showing pre‑post reductions in total medical costs for employers.

Pattern Detected

Recent positive clinical and commercial updates have often met with muted or negative price reactions, especially around financial results.

Recent Company History

Over the past month, DarioHealth reported multiple data-driven and commercial milestones, including JMIR Cardio blood pressure outcomes on Dec 4, 2025 and exceeding its 2025 new client target on Dec 2, 2025, both followed by modest gains. Earlier in November, strong real-world cost-savings data and Q3 2025 earnings coincided with sharper declines, including a -15.57% move after results. Today’s AI-layer launch extends the theme of leveraging data and AI across its cardiometabolic platform.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-10-20

An active S-3 resale registration dated Oct 20, 2025 covers up to 2,713,180 shares offered by selling stockholders. The company will not receive proceeds from these sales but bears registration expenses, so this filing mainly affects potential secondary liquidity rather than providing new primary capital.

Market Pulse Summary

The stock is up +9.3% following this news. A strong positive reaction aligns with prior AI-related news, where an earlier AI-tagged event saw a 4.79% gain. The launch of DarioIQ embeds AI directly into the hypertension experience, building on extensive real-world data and prior outcomes research. Investors reviewing sustainability could weigh past instances where favorable clinical and economic data sometimes preceded pullbacks, as well as the existing S-3 resale registration that may affect secondary supply.

Key Terms

genai technical

"represents a foundational step in Dario's evolutionary GenAI roadmap, with patient"

Generative AI (genai) is a type of artificial intelligence designed to create new content, such as text, images, or music, that resembles human-produced work. It matters to investors because it has the potential to transform industries by automating tasks, enhancing creativity, and enabling new products and services, which can influence company performance and market opportunities.

biometric medical

"integrates behavioral insights, real-time biometric interpretation and personalized guidance,"

Biometric describes measurements of unique physical or behavioral traits—like fingerprints, face shape, voice, or the way someone types—used to identify or verify a person. For investors, biometrics matter because they underpin products and services that promise stronger security or convenience, create new market opportunities, and raise regulatory and privacy risks that can affect a company’s costs, customer trust, and long-term value.

conversational ai technical

"multi-phase introduction of conversational AI designed to enhance, not replace, the"

Conversational AI is technology that allows computers to understand, process, and respond to human language in a way that feels natural and interactive, similar to chatting with a person. It enables machines to hold conversations, answer questions, and assist with tasks automatically. For investors, it matters because this technology can improve customer service, streamline operations, and create new opportunities across many industries.

AI-generated analysis. Not financial advice.

First in-market activation of Dario's GenAI roadmap lays clinical and technical foundation for a seamless, conversational AI experience across the entire Dario platform

DarioIQ™ reflects years of innovation in data science, engineering and clinical design backed by Dario's proprietary AI models and 13 billion real-world data points, further reinforcing Dario's position as a leader in digital health

NEW YORK, Dec. 10, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the launch of the Dario Health app enhanced with DarioIQ™, the Company's new artificial intelligence ("AI") layer, delivered as a direct-to-consumer first version for an initial cohort of hypertension members who enrolled to access the new experience. This launch marks the first major milestone in Dario's multi-phase introduction of conversational AI designed to enhance, not replace, the human-centered guidance central to chronic condition management.

The introduction of DarioIQ™ adds a clinically aligned, conversational layer that operates side-by-side with Dario's data and experience-driven mobile application. The system integrates behavioral insights, real-time biometric interpretation and personalized guidance, supported by seamless medical-device connectivity and Dario's existing human coaching framework. This deployment represents a foundational step in Dario's evolutionary GenAI roadmap, with patient safety at the forefront.

Dario began with a direct-to-consumer hypertension support to anchor DarioIQ™ in a high-impact condition area while refining the integrated conversational experience, before expanding across the full suite of Dario solutions for employers and health plans. This phase will inform expansion across diabetes, weight management, behavioral health, musculoskeletal conditions and additional chronic pathways.

Members in the initial cohort opted in specifically to use the enhanced experience, ensuring transparency and maintaining trust in the company's introduction of DarioIQ™.

Dario selected its direct-to-consumer marketspace to refine user interactions and evaluate safety and performance within a controlled, mature ecosystem. This approach allows Dario to bring a fully validated, evidence-supported AI capability to its business-to-business ("B2B") partners – avoiding risks associated with unproven or hypothetical generative models.

"The introduction of DarioIQ™ into the hands of real hypertension users represents a major moment for Dario," said Lara Dodo, Chief Operating Officer at Dario. "Our AI is intentionally designed to complement, and not replace, the human experience of managing chronic conditions. By launching a direct-to-consumer first version, we will be able to learn from real engagement, ensure safety and clinical alignment, and deliver a mature, evidence-based capability to our employer and payer partners. This is the foundation for the unified GenAI experience that will power the next generation of Dario's platform."

DarioIQ™ combines three AI-driven components: Advisor, which delivers personalized guidance; Sentinel, which provides timely interventions to keep users engaged; and Strategist, which turns member data into actionable insights and measurable value. These capabilities build on Dario's proprietary AI models and over 13 billion real-world data points, reinforcing Dario's position as a leader in digital health.

"DarioIQ™ reflects years of innovation in data science, engineering and clinical design," said Galya Gorodinsky, Senior Vice President, Research and Development, and Delivery Solutions. "Starting with hypertension allows us to validate the full experience – from device data interpretation to adaptive, conversational guidance – while maintaining clear safety guardrails. This rollout ensures operational stability as we extend AI throughout Dario's growing ecosystem."

About DarioHealth Corp. (NASDAQ: DRIO)

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.  

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses that the Company expects that its GenAI roadmap will enable a seamless conversational AI experience across the platform; that the introduction of DarioIQ™ represents a major moment for Dario; the future expansion of DarioIQ™ across additional chronic conditions; that the GenAI experience is expected to power the next generation of the Company's platform; that by launching a direct-to-consumer version, it expects that it will be able to learn from real engagement, ensure safety and clinical alignment, and deliver a mature, evidence-based capability to its employer and payer collaborations; and the future benefits of the DarioIQ™ for users. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310

Rob Halpern
SVP Marketing
irteam@dariohealth.com 

Logo - http://mma.prnewswire.com/media/544126/DarioHealth_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/dario-launches-darioiq-ai-integration-in-dario-health-app-with-direct-to-consumer-first-version-for-hypertension-members-302636023.html

SOURCE DarioHealth Corp.

FAQ

What is DarioIQ™ and when did Dario Health (DRIO) launch it?

DarioIQ™ is a conversational AI layer in the Dario Health app; it launched on Dec 10, 2025 for an opt-in hypertension cohort.

Which Dario Health members get the DarioIQ™ direct-to-consumer experience first?

Initial access is for an opt-in cohort of members with hypertension who enrolled to test the enhanced experience.

How does DarioIQ™ work within the Dario app (DRIO)?

DarioIQ™ combines Advisor (personalized guidance), Sentinel (timely interventions) and Strategist (actionable insights) using device data and human coaching.

Will Dario expand DarioIQ™ beyond hypertension and to which areas?

Yes; the company intends to expand DarioIQ™ to employers and health plans and additional pathways including diabetes, weight management, behavioral health and musculoskeletal conditions.

What safety and validation approach is Dario Health using for DarioIQ™?

Dario deployed a direct-to-consumer first rollout with opt-in members to refine interactions, evaluate safety and clinical alignment before broader B2B deployment.